Memantine Hydrochloride Tablet
Product Images NDC 72162-2004

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 72162-2004). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 01)

Chemical structure of Memantine Hydrochloride, showing its bicyclic amine framework with attached methyl groups and hydrochloride component as indicated by NH2 and HCl labels.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 02)

A line graph showing the mean change from baseline in ADCS-ADL scores over 28 weeks of treatment comparing Memantine Hydrochloride (10 mg) and placebo. The graph depicts clinical improvement and decline, with Memantine Hydrochloride showing less decline over time compared to placebo, both with error bars.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 03)

A line graph comparing the cumulative percentage of patients versus ADCS-ADL change from baseline for Memantine Hydrochloride (M.HCl) and placebo groups. The graph shows two curves, one with circular markers for M.HCl and one with square markers for placebo, illustrating patient response distribution over a range of negative changes.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 04)

A line graph showing the mean change from baseline in SIB score over 28 weeks of treatment comparing Placebo and Memantine Hydrochloride (M.HCl). The y-axis represents mean change with SEM, and the x-axis represents weeks of treatment. The graph includes labeled markers for clinical improvement and clinical decline, with Placebo showing a decline and M.HCl maintaining scores around baseline.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 05)

A cumulative percentage of patients graph depicting change from baseline in Swollen and Tender Joint Index (SIB) scores. The x-axis shows SIB change from baseline ranging approximately from +15 to -30, and the y-axis shows cumulative percentage of patients from 0 to 100%. Two data series are shown: one for placebo marked by filled squares, and one for Memantine Hydrochloride (M. HCl) marked by open circles. The graph compares these two treatment groups over the range of SIB change values.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 06)

A line graph showing the mean change from baseline in ADCS-ADL scores over 24 weeks of treatment comparing Placebo/Donepezil and Memantine Hydrochloride (M.HCl)/Donepezil. The y-axis represents mean change with SEM, ranging from clinical improvement to clinical decline. The x-axis represents weeks of treatment from 0 to 24.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 07)

A line graph showing cumulative percentage of patients on the y-axis and ADCS-ADL change from baseline on the x-axis. Two data series are presented: Placebo/Donepezil (squares) and Memantine Hydrochloride (M. HCl)/Donepezil (circles), illustrating differences in patient outcomes over a range of baseline changes.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 08)

Line graph showing mean change from baseline in SIB score over 24 weeks of treatment. Two lines compare Placebo/Donepezil (squares) and Memantine Hydrochloride/Donepezil (circles) groups. The y-axis measures mean change ranging from -4 to +4; the x-axis shows weeks of treatment from 0 to 24. The graph indicates clinical improvement above zero and clinical decline below zero.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 09)

A cumulative percentage graph showing patient response differences between Memantine Hydrochloride with Donepezil and Placebo with Donepezil. The x-axis represents SIB change from baseline, while the y-axis indicates the cumulative percentage of patients. Two curves depict response trends for each treatment group.*

FDA Label Image

Label (Lbl721622004)

Memantine Hydrochloride Tablets, USP 10 mg oral tablets in a bottle containing 500 tablets. The label includes NDC 72162-2004-5 and states the product is prescription only. Labeled by Bryant Ranch Prepack and manufactured by Zydus Lifesciences Ltd. Storage instructions specify 20° to 25°C and dispensing in a tight container.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.